BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced that its Chief Scientific Advisor and Co-Founder, Eric N. Olson, Ph.D., has been named the winner of the prestigious Grand Prize of the Institut de France’s Fondation Lefoulon-Delalande. The award, which is widely considered the most distinguished in the cardiovascular field, is in recognition of his groundbreaking research into the mechanisms of gene regulation in heart development and the subsequent creation of new therapeutic approaches for the treatment of heart disease. Professor Alain Carpentier, President of the Scientific Council of the Fondation Lefoulon-Delalande, will present the prize on June 10 in Paris.
